Utilizing immunotherapy towards achieving a functional cure for HIV-1

Autor(es)

Sugiyama, Fabricia Heloisa Cavicchioli ; Dietz, Lisa Lokso ; Sogaard, Ole Schmeltz

• Tipo de documento: Artigo Científico
• Fonte: CURRENT OPINION IN HIV AND AIDS; v. 19, n. 4, p. 7-pg., 2024-07-01.

Resumo

Purpose of reviewAdvancements in antiretroviral therapy (ART) have positively impacted the life expectancy and possibility of living a normal life for people with HIV-1. However, lifelong daily medication is necessary to prevent disease progression. To this end, immunotherapeutic strategies are being tested with the aim of developing a functional cure in which the immune system effectively controls HIV-1 in the absence of ART.Recent findingsThe most promising advances in achieving sustained HIV-1 remission or cure include broadly neutralizing antibodies (bNAbs) that are administered alone or in combination with other agents. Newer and more innovative approaches redirecting T cells or natural killer cells to kill HIV-1 infected cells have also shown promising results. Finally, multiple ongoing trials focus on combining bNAbs with other immune-directed therapies to enhance both innate and adaptive immunity.SummaryWhile immunotherapies as an alternative to conventional ART have generally proven to be well tolerated, these therapeutic approaches have largely been unsuccessful in inducing ART-free control of HIV-1. However, promising results from recent trials involving bNAbs that have reported durable HIV-1 control among a subset of participants, provide reason for cautious optimism that we with further optimization of these treatment strategies may be able to achieve functional cure for HIV-1. (AU)

• Processo FAPESP: 20/02354-8 - Efeito do tratamento com epidrugs: repercussão sobre o training das células do sistema imune inato de pacientes HIV+
• Beneficiário: Fabrícia Heloisa Cavicchioli Sugiyama
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 23/02721-9 - Imunofenotipagem espectral de células imunes inatas de pessoas vivendo com HIV tratadas com agonista TLR9 e bNAbs
• Beneficiário: Fabrícia Heloisa Cavicchioli Sugiyama
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado Direto